Henry Schein Earnings Reports

Henry Schein Inc. delivered a solid fourth quarter, achieving a 5.8% increase in total net sales. GAAP net income surged to $94 million, and non-GAAP net income increased to $149 million. Adjusted EBITDA also rose significantly to $270 million, reflecting strong operational performance. The company’s restructuring efforts contributed to cost efficiencies, supporting future growth.

Henry Schein's third-quarter results for 2024 showed a slight increase in total net sales, driven by acquisitions and the successful implementation of their BOLD+1 Strategic Plan. The company's GAAP diluted EPS was $0.78, and non-GAAP diluted EPS was $1.22. They have increased their full-year non-GAAP EPS guidance to $4.74 to $4.82.

Henry Schein reported a 1.1% increase in total net sales for the quarter, reaching $3.1 billion. GAAP diluted EPS was $0.80, while non-GAAP diluted EPS was $1.23. The company updated its full-year non-GAAP EPS guidance to $4.70 to $4.82 and announced a new restructuring plan targeting $75 million to $100 million in annual run-rate savings.

Henry Schein's first-quarter financial results for 2024 reflect solid earnings driven by gross margin expansion and a strong recovery from last quarter’s cyber incident. The company reported a sales growth of 3.7% compared to the first quarter of 2023.

Henry Schein reported Q4 2023 financial results, with total net sales of $3.0 billion, a decrease of 10.5% compared to Q4 2022. GAAP net income was $18 million, or $0.13 per diluted share, and non-GAAP net income was $86 million, or $0.66 per diluted share. The results were impacted by a cybersecurity incident and acquisition-related expenses.

Henry Schein reported a 3.1% increase in total net sales, reaching $3.2 billion. GAAP diluted EPS was $1.05, and non-GAAP diluted EPS was $1.32. The company is updating its full-year non-GAAP diluted EPS guidance to $4.43 to $4.71, reflecting softening macroeconomic conditions and the impact of a recent cybersecurity incident.

Henry Schein reported a 2.3% increase in total net sales for Q2 2023, reaching $3.1 billion. GAAP diluted EPS was $1.06, while non-GAAP diluted EPS was $1.31. The company affirms its 2023 non-GAAP diluted EPS guidance of $5.18 to $5.35.

Henry Schein reported a decrease of 3.8% in net sales compared to Q1 2022, with sales totaling $3.1 billion. GAAP diluted EPS was $0.91, and non-GAAP diluted EPS was $1.21. Excluding PPE products and COVID-19 test kits, internal sales growth in local currencies was 6.3%. The company is updating its full-year 2023 non-GAAP diluted EPS guidance to $5.18 to $5.35.

Henry Schein reported a slight increase in fourth-quarter net sales, but GAAP diluted EPS decreased significantly. The company introduced 2023 financial guidance, expecting operating income growth when excluding the contribution from PPE products and COVID-19 test kits.

Henry Schein reported a decrease in net sales by 3.5% compared to Q3 2021, but an increase in non-GAAP diluted EPS from $1.10 to $1.15. The company's internal sales increased by 6.8% in local currencies when excluding sales of PPE and COVID-19 test kits. The company narrows its 2022 non-GAAP diluted EPS guidance range, reflecting confidence in the business's strength.

Henry Schein reported a 2.1% increase in net sales, reaching $3.0 billion. GAAP diluted EPS increased to $1.16, compared to $1.10 in the second quarter of 2021. The company reaffirmed its full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91.

Henry Schein reported record first-quarter financial results with net sales of $3.2 billion, an increase of 8.7% compared to the first quarter of 2021. GAAP diluted EPS was $1.30, compared to $1.16 in the first quarter of 2021. The company affirmed its full-year 2022 GAAP diluted EPS guidance of $4.75 to $4.91.

Henry Schein reported Q4 2021 total net sales of $3.3 billion, up 5.2% compared with prior-year. Fourth-quarter GAAP diluted EPS from continuing operations of $1.05 compared with prior-year GAAP diluted EPS from continuing operations of $0.99. Fourth-quarter non-GAAP diluted EPS from continuing operations of $1.07 compared with prior-year non-GAAP diluted EPS from continuing operations of $1.00.

Henry Schein reported record third-quarter financial results with net sales of $3.2 billion, up 11.9% year-over-year. GAAP diluted EPS was $1.15, compared to $0.99 in the prior year, and non-GAAP diluted EPS was $1.10, compared to $1.03 in the prior year. The company increased its 2021 non-GAAP diluted EPS guidance to a range of $4.27 to $4.35 and introduced preliminary guidance for 2022.

Henry Schein reported record second-quarter financial results from continuing operations, with total net sales of $3.0 billion, up 76.2% compared to the prior year and up 21.2% versus 2019. GAAP diluted EPS was $1.10, and non-GAAP diluted EPS was $1.11. The company raised its guidance for 2021 non-GAAP diluted EPS to be at or above $3.85.

Henry Schein reported record first-quarter financial results from continuing operations, with total net sales of $2.9 billion, a 20.4% increase compared to the first quarter of 2020. GAAP diluted EPS from continuing operations was $1.16, and non-GAAP diluted EPS from continuing operations was $1.24. The company raised its guidance for 2021 non-GAAP diluted EPS to be at or above $3.70.

Henry Schein reported a strong Q4 2020 with total net sales reaching $3.2 billion, an 18.6% increase year-over-year, driven primarily by PPE and COVID-19 related product sales. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS was $1.00. The company's dental and medical segments showed growth, with medical experiencing a significant surge due to COVID-19 related demand.

Henry Schein reported record third quarter financial results, with net sales reaching $2.8 billion, a 13.2% increase compared to the third quarter of 2019. GAAP diluted EPS from continuing operations was $0.99, and non-GAAP diluted EPS from continuing operations was $1.03. The company's performance was driven by sales of PPE and COVID-19-related products.

Henry Schein reported a decrease in net sales by 31.2% compared to Q2 2019, with a GAAP net loss of $11.4 million, or $0.08 per diluted share. The results reflect the impact of COVID-19, particularly in the Dental business, but sales improved as the quarter progressed due to the resumption of operations for dental and medical customers.

Henry Schein reported a 2.9% increase in net sales to $2.4 billion for Q1 2020. GAAP diluted EPS from continuing operations was $0.91, and non-GAAP diluted EPS was $0.94. The company's results were significantly impacted by the COVID-19 pandemic, particularly in the Dental business.

Henry Schein reported a 7.9% increase in net sales from continuing operations, reaching $2.7 billion. GAAP diluted EPS was $2.25, up 192.2% year-over-year, while non-GAAP diluted EPS was $0.97, a 9.0% increase. The company affirms its 2020 non-GAAP diluted EPS guidance of $3.65 to $3.75.